ActiveNCT07554157

Establishment of a Pan-Cancer Screening Model Based on Blood Biomarkers

Sponsor: Zhejiang Cancer Hospital

Trial Details

Condition	Neoplasms
Intervention	No intervention
Status	Active
Participants	10,000,000
Est. Completion	31 July 2027
Last Updated	28 Apr 2026

Primary Outcome

Area under the ROC curve (AUC); Sensitivity of the model; Specificity of the model

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Pathologically confirmed cancer patients (for case group) OR individuals without cancer (for control group) * Age between 18 and 80 years * Complete clinical data and blood test results (complete blood count, biochemistry, coagulation panel, tumor markers) available * No history of other organic diseases (excluding cancer) Exclusion Criteria: * Presence of organic diseases other than cancer (e.g., severe heart, liver, kidney disease) * Hematologic disorders or immunodeficiency diseases (e.g., AIDS) * Incomplete data or missing timeline records

Trial Sites

Countries

China

View Registry Entry

Related Analysis

Massive 10-Million Patient Study Develops Blood-Based Pan-Cancer Screening Model — Clinical Implications for Early Detection

A groundbreaking 10-million patient retrospective study from China develops machine learning models to detect multiple cancer types using routine blood tests. This research could revolutionise population-based cancer screening through accessible, cost-effective blood biomarker analysis.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service